Molecular Targeting Technologies
Pharmaceuticals, 833 Lincoln Ave, West Chester, Pennsylvania, 19380, United States, 1-10 Employees
Phone Number: +12*********
Who is MOLECULAR TARGETING TECHNOLOGIES
A clinical stage business, developing theranostics for rare cancers. A Centocor spinoff, were rooted in a decade of innovative collaborative research, a robust pipeline and an outstanding...
Read More
-
Headquarters: 833 Lincoln Ave, West Chester, Pennsylvania, 19380, United States
-
Date Founded: 2011
-
Employees: 1-10
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
-
CEO:
Chris Pak
Email
Phone
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 541720 |
Show More
Does something look wrong? Fix it. | View contact records from MOLECULAR TARGETING TECHNOLOGIES
Molecular Targeting Technologies Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Molecular Targeting Technologies
Answer: Molecular Targeting Technologies's headquarters are located at 833 Lincoln Ave, West Chester, Pennsylvania, 19380, United States
Answer: Molecular Targeting Technologies's phone number is +12*********
Answer: Molecular Targeting Technologies's official website is https://mtarget.com
Answer: Molecular Targeting Technologies's revenue is $5 Million to $10 Million
Answer: Molecular Targeting Technologies's SIC: 2834
Answer: Molecular Targeting Technologies's NAICS: 541720
Answer: Molecular Targeting Technologies has 1-10 employees
Answer: Molecular Targeting Technologies is in Pharmaceuticals
Answer: Molecular Targeting Technologies contact info: Phone number: +12********* Website: https://mtarget.com
Answer: A clinical stage business, developing theranostics for rare cancers. A Centocor spinoff, were rooted in a decade of innovative collaborative research, a robust pipeline and an outstanding scientific network. In clinical development: EBTATE (177Lu-EBTATE) A long lived radiotherapeutic for gastroenteropancreatic neuroendocrine and Hurthle cell thyroid tumors (under license from the NIH) Early human testing showed EBTATE is safe and more effective than competitors. US trials begin in Q4 2021 at Memorial Sloan Kettering Cancer Center. EBRGD (177Lu-EBRGD) A long-lived radiotherapeutic for v3 expressing tumors. We're targeting glioblastoma multiforme and non-small cell lung cancer. (under license from the NIH). Trials planned in 2022. FGA (18F-fluoroglucaric acid) A PET radiodiagnostic targeting histones released during necrosis and cell death. Focused on tumor response to chemotherapy of brain and lung cancers. TDURA (99mTc-duramycin) A SPECT radiodiagnostic targeting phosphatidylethanolamine, exposed on cell surfaces during cell death. Focused on very early visualization of tumor death during chemotherapy, distinguishing responders from non-responders in one day. Phase 0/I trials in colorectal tumor response to therapy underway at the University of Antwerp.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month